Bausch Health Co. Inc. (BHC) – Company Press Releases
-
Bausch Health to Announce First-Quarter 2024 Results on May 2
-
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
-
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
-
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
-
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative
-
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversation
-
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
-
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
-
Bausch Health Companies to Present at Cowen Annual Health Care Conference
-
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
-
Salix Announces 2024 Gastrointestinal Health Scholars Program
-
Bausch Health Announces Board Refreshment
-
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
-
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
-
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
-
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
-
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
-
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
-
KBRA Releases Third-Quarter 2023 U.S. Bank Compendium and 2024 Outlook
-
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, Accor
-
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
-
Bausch Health Announces Third-Quarter 2023 Results
-
Bausch Health Announces Third-Quarter 2023 Results
-
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
-
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
-
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
-
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk
-
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
-
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
-
Salix Pharmaceuticals Partners with Bellamy Young
-
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
-
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch He
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Nation, Bausch, and Applied Digital and Encourages Investors to Contact the Firm
-
BHC INVESTOR DEADLINE APPROACHING: Robbins Geller Rudman & Dowd LLP Announces that Bausch Health Companies Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action – BHC
-
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bausch, Applied Digital, and Infinity and Encourages Investors to Contact the Firm
-
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch He
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Nation, Bausch, and Applied Digital and Encourages Investors to Contact the Firm
-
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch He
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against KeyCorp, Live Nation, and Bausch and Encourages Investors to Contact the Firm
-
BAUSCH HEALTH COMPANIES INC. DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Compani
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Nation, Bausch, and Applied Digital and Encourages Investors to Contact the Firm
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC
-
BAUSCH HEALTH COMPANIES INC. (NYSE: BHC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch He
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against KeyCorp, Live Nation, and Bausch and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bausch, and Applied Digital and Encourages Investors to Contact the Firm
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC
-
KBRA Releases Second-Quarter 2023 U.S. Bank Compendium
-
BHC DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc.
Back to BHC Stock Lookup
